Chest pain centers are built around rapid recognition of life-threatening causes of chest pain, especially acute coronary syndrome (ACS) and acute myocardial infarction (AMI). High-sensitivity cardiac troponin is central to modern chest pain pathways, but it must be interpreted together with symptoms, ECG findings, clinical risk and serial change. When quantitative CLIA testing is available close to the patient, clinicians can reduce waiting caused by sample transport and central-lab queues, supporting faster review and clearer next steps.
|
Core message POCT does not replace the chest pain pathway. It strengthens it by placing fast, quantitative cardiac biomarkers closer to emergency decision-making. |
In acute chest pain, a single marker rarely answers every question. Troponin supports myocardial injury assessment, while complementary markers can help clinicians consider heart failure, pulmonary embolism, reinfarction or broader cardiovascular risk when used with clinical probability and imaging.
|
Clinical question |
Useful markers |
Clinical role |
|
Suspected ACS / AMI |
hs-cTnT + MYO + CK-MB |
Troponin is central for myocardial injury; MYO/CK-MB may support early injury or reinfarction assessment. |
|
Chest pain with dyspnea or respiratory failure |
hs-cTnT + D-Dimer + BNP / NT-proBNP |
Supports differentiation between myocardial injury, pulmonary embolism risk and heart-failure burden. |
|
Heart failure assessment |
BNP / NT-proBNP |
Helps evaluate suspected congestive heart failure and severity together with clinical findings. |
|
PE / DVT assessment in non-high probability patients |
D-Dimer |
Supports exclusion strategies when combined with clinical probability assessment and local protocols. |
|
Assay |
Sample |
Time |
Volume |
Measuring range |
|
Plasma |
5 min |
50 µL |
0.25-20 mg/L |
|
|
Plasma |
5 min |
100 µL |
15-5000 pg/mL |
|
|
Plasma |
5 min |
100 µL |
15-35000 pg/mL |
|
|
Serum / Plasma |
5 min |
50 µL |
0.3-300 ng/mL |
|
|
Serum / Plasma |
5 min |
50 µL |
21-3000 ng/mL |
|
|
Serum / Plasma |
10 min |
200 µL |
5-10000 ng/L |
|
C5000 platform highlights · Fast result availability: Cardiac assays are designed for 5-10 minute testing, helping clinicians review biomarkers during the initial emergency workflow. · Flexible cardiac panel: Seven independent test positions support time-independent combinations such as hs-cTnT, CK-MB, MYO, D-Dimer, BNP and NT-proBNP. · Compact deployment: The C5000 platform is small, portable and suitable for near-patient testing zones such as emergency departments, chest pain units and satellite labs. |
Operational fit · Simplified logistics: Lyophilized reagents support room-temperature transport/storage and reduce dependence on cold-chain logistics. · Connected workflow: LIS/HIS transmission supports real-time information sharing and reduces manual reporting delay. |
|
Blog closing In a chest pain center, faster biomarker access is not just a laboratory upgrade. It can support earlier review, more structured serial testing and more confident patient disposition when combined with ECG, clinical risk assessment and local ACS protocols. |
Looking for a compact CLIA cardiac testing solution for emergency chest pain workflows? Contact Poclight to learn how C5000 can support rapid, flexible and connected myocardial marker testing close to the point of care.
伝言を残す
スキャンしてWeChatに送信 :